Effects of SKF 108922, an HIV-1 protease inhibitor, on retrovirus replication in mice

Antiviral Research

Volumn 29, Issue 2-3, 1996, Pages 175-186

  Black, Paul L ^a   Ussery, Michael A ^a   Barney, Shawn ^b,c   Wittrock, Robert ^c   DeMarsh, Peter ^c   Dreyer, Geoffrey B ^c,d   Petteway Jr , Stephen R ^c,d   Dalmonte, Paul ^c   Baldoni, John ^c   Lambert, Dennis M ^b,c  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b Trimeris Inc   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

^d BAYER CORPORATION   (United States)

Author keywords

animal model; murine leukemia virus; murine retrovirus; protease inhibitor

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CHOLESTEROL SULFATE; DRUG VEHICLE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; SKF 108922; SKF 109273; SKF 109274; UNCLASSIFIED DRUG; VIRUS ENZYME;

ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; COLLOID; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG SYNTHESIS; EXPERIMENTAL INFECTION; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PHARMACEUTICS; PRIORITY JOURNAL; RAUSCHER LEUKEMIA VIRUS; RETROVIRUS; SPLENOMEGALY; SUBCUTANEOUS DRUG ADMINISTRATION; SUSPENSION; VIREMIA; VIRUS INFECTION; VIRUS REPLICATION;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; LENTIVIRUS; MURINAE; MURINE LEUKEMIA VIRUS; RAUSCHER MURINE LEUKEMIA VIRUS; SIMIAE; SIMIAN IMMUNODEFICIENCY VIRUS; UNIDENTIFIED RETROVIRUS;

EID: 18344398320     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/0166-3542(95)00831-4     Document Type: Article

References (43)

1. Abdel-Meguid, S.S., Metcalf, B.W., Carr, T.J., DeMarsh, P.J., DesJarlais, R.I., Fisher, S., Green, D.A., Ivanoff, L., Lambert, D.M., Murthy, K.H., Petteway, S.R., Jr., Tomaszek, T.A., Winbone, E., Zhao, B., Dreyer, G.B. and Meek, T.D. (1994) Inhibition of HIV-1 protease by an orally-bioavailable inhibitor containing an imidazole-derived peptide bond replacement: Crystallographic and pharmacokinetic analysis. Biochemistry 33, 11671-11677.
2. Anand, R., Nayyar, S., Pitha, J. and Merril, C.R. (1990) Sulphated sugar alpha-cyclodextrin sulphate, a uniquely potent anti-HIV agent, also exhibits marked synergism with AZT, and lymphoproliferative activity. Antiviral Chem. Chemother. 1, 41-46.
3. Berger, S.A., Sanderson, N., Bernstein, A. and Handkins, W.D. (1985) Induction of the early stages of Friend erythroleukemia with helper-free Friend spleen focus-forming virus. Proc. Natl. Acad. Sci. USA 82, 6913-6917.
4. Bestwick, R.K., Handkins, W.D. and Kabat, D. (1985) Roles of helper and defective retroviral genomes in murine erythroleukemia: Studies of spleen focus-forming virus in the absence of helper. J. Virol. 56, 660-664.
5. Black, P.L., Ussery, M.A., Rankin, J.T., Jr. and Chirigos, M.A. (1990) Therapeutic activity of reverse transcriptase inhibitors in murine retrovirus models. Ann. NY Acad. Sci. 616, 486-489.
6. Black, P.L., Downs, M.B., Lewis, M.G., Ussery, M.A., Dreyer, G.B., Petteway, S.R., Jr. and Lambert, D.M. (1993) Antiretroviral activities of protease inhibitors against murine leukemia virus and simian immunodeficiency virus in tissue culture. Antimicrob. Agents Chemother. 37, 71-77.
7. Chirigos, M.A. (1964) Studies with the murine leukemogenic Rauscher virus. III. An in vivo assay for anti-viral agents. Cancer Res. 24, 1035-1041.
8. Chirigos, M.A., Ussery, M.A., Rankin, J.T., Jr., Herrmann, D., Bicker, U. and Black, P.L. (1990) Antiviral efficacy of imexon in the Rauscher murine retrovirus AIDS model. Immunopharm. Immunotox. 12, 1-21.
9. Chung, S., Wolff, L. and Ruscetti, S. (1987) Sequences responsible for the altered erythropoietin responsiveness in spleen focus-forming virus strain SFFVp-infected cells are localized to a 678-base-pair region at the 3′ end of the envelope gene. J. Virol. 61, 1661-1664.
10. Coffin, J.M. (1985) Genome structure. In: R. Weiss, N. Teich, H. Varmus and J. Coffin (Eds.), RNA Tumor Viruses, 2nd edn. Cold Spring Harbor Laboratory, New York, pp. 17-74.
11. Crawford, S. and Goff, S.P. (1985) A deletion mutation in the 5′ part of the pol gene of Moloney murine leukemia virus blocks proteolytic processing of the gag and pol polyproteins. J. Virol. 53, 899-907.
12. Dreyer, G.B., Metcalf, B.W., Tomaszek, T.A., Jr., Carr, T.J., Chandler, A.C., III, Hyland, L., Moore, M.L., Strickler, J.E., Debouck, C. and Meek, T.D. (1989) Inhibition of human immunodeficiency virus 1 protease in vitro: Rational design of substrate analogue inhibitors. Proc. Natl. Acad. Sci. USA 86, 9752-9756.
13. Dreyer, G.B., Lambert, D.M., Meek, T.D., Carr, T.J., Tomaszek, T.A., Jr., Fernandez, A.V., Bartus, H., Cacciavillani, E., Hassel, A.M., Minnich, M., Petteway, S.R., Jr., Metcalf, B.W. and Lewis, M. (1992) Hydroxyethylene isostere inhibitors of human immunodeficiency virus-1 protease: Structure-activity analysis using enzyme kinetics. X-ray crystallography, and infected T-cell assays. Biochemistry 31, 6646-6659.
14. Gardner, M.B. and Luciw, P.A. (1989) Animal models of AIDS. FASEB J. 3, 2593-2606.
15. Goff, S., Traktman, P. and Baltimore, D. (1981) Isolation and properties of Moloney murine leukemia virus mutants: Use of a rapid assay for release of virion reverse transcriptase. J. Virol. 38, 239-248.
16. Gottlinger, H.G., Sodroski, J.G. and Haseltine, W.A. (1989) Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 86, 5781-5785.
17. Guo, L.S.S., Fielding, R.M., Lasic, D.D., Hamilton, R.L. and Mufson, D. (1991) Novel antifungal drug delivery: Stable Amphotericin B-cholesteryl sulfate discs. Int. J. Pharm. 75, 45-54.
18. Hollingshead, M.G., Westbrook, L., Ross, M.J., Bailey, J., Quails, K.J. and Allen, L.B. (1992) An ELISA system for evaluating antiretroviral activity against Rauscher murine leukemia virus. Antiviral Res. 18, 267-274.
19. Katoh, I., Yoshinaka, Y., Rein, A., Shibuya, M., Odaka, T. and Oroszlan, S. (1985) Murine leukemia virus maturation: Protease region required for conversion from 'immature' to 'mature' core form and for virus infectivity. Virology 145, 280-292.
20. Katoh, I., Yasunaga, T., Ikawa, Y. and Yoshinaka, Y. (1987) Inhibition of retroviral protease activity by an aspartyl proteinase inhibitor. Nature 329, 654-656.
21. Kohl, N.E., Emini, E.A., Schleif, W.A., Davis, L.J., Heimbach, J.C., Dixon, R.A., Scolnick, E.M. and Sigal, I.S. (1988) Active human immunodeficiency virus protease is required for viral infectivity. Proc. Natl. Acad. Sci. USA 85, 4686-4690.
22. Kramer, R.A., Schnaber, M.D., Skalka, A.M., Ganguly, K., Wong-Staal, F. and Reddy, E.P. (1986) HTLV-III gag protein is processed in yeast cells by the virus pol-protease. Science 231, 1580-1584.
23. Kräusslich, H.-G. and Wimmer, E. (1988) Viral proteinases. Ann. Rev. Biochem. 57, 701-754.
24. Lai, M.T., Hui, K., Tang, J., Dee, A., Bowdon, B., Buckheit, R., Margolin, N., Vlahos, C. and Colacino, J. (1991) Statine-based inhibitors of HIV-1 protease block the production of infectious progeny virus in HIV-1 infected human T4 cells and in mouse fibroblasts infected with murine leukemia virus. VII International Conference on AIDS, Florence, Abstract No. WA1005.
25. Lai, M.T., Tang, J., Wroblewski, V., Dee, A.G., Margolin, N., Vlahos, C., Bowdon, B., Buckheit, R., Colacino, J. and Hui, K.Y. (1993) Impeded progression of Friend disease in mice by an inhibitor of retroviral proteases. JAIDS. 6, 24-31.
26. Lambert, D.M., Petteway, S.R., McDanal, C.E., Hart, T.K., Leary, J.J., Dreyer, G.B., Meek, T.D., Bugelski, P.J., Bolognesi, D.P., Metcalf, B.W. and Matthews, T.J. (1992) Human immunodeficiency virus type 1 protease inhibitors irreversibly block infectivity of purified virions from chronically infected cells. Antimicrob. Agents Chemother. 36, 982-988.
27. McQuade, T.J., Tomasselli, A.G., Liu, L., Karacostas, V., Moss, B., Sawyer, T.K., Heinrikson, R.L. and Tarpley, W.G. (1990) A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation. Science 247, 454-456.
28. Meek, T.D., Dayton, B.D., Metcalf, B.W., Dreyer, G.B., Strickler, J.E., Gorniak, J.G., Rosenberg, M., Moore, M.L., Magaard, V.W. and Debouck, C. (1989) Human immunodeficiency virus 1 protease expressed in Escherichia coli behaves as a dimeric aspartic protease. Proc. Natl. Acad. Sci. USA 86, 1841-1845.
29. Meek, T.D., Lambert, D.M., Dreyer, G.B., Carr, T.J., Tomaszek, T.A., Jr., Moore, M.L., Strickler, J.E., Debouck, C., Hyland, L.J., Metcalf, B.W. and Petteway, S.R., Jr. (1990) Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analogues. Nature 343, 90-92.
30. Miller, M., Jaskolski, M., Rao, J.K., Leis, J. and Wlodawer, A. (1989) Crystal structure of a retroviral protease proves relationship to aspartic protease family. Nature 337, 576-579.
31. Mous, J., Heimer, E.P. and LeGrice, S.F. (1988) Processing protease and reverse transcriptase from human immunodeficiency virus type I polyprotein in Escherichia coli. J. Virol. 62, 1433-1436.
32. Navia, M.A., Fitzgerald, P.M., McKeever, B.M., Leu, C.T., Heimbach, J.C., Herber, W.K., Sigal, I.S., Darke, P.L. and Springer, J.P. (1989) Three-dimensional structure of aspartyl protease from human immune deficiency virus HIV-1. Nature 337, 615-620.
33. Pearl, L.H. and Taylor, W.R. (1987a) A structural model for the retroviral proteases. Nature 329, 351-354.
34. Pearl, L.H. and Taylor, W.R. (1987b) Sequence specificity of retroviral proteases. Nature 338, 482.
35. Peng, C., Ho, B.K., Chang, T.W. and Chang, N.T. (1989) Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity. J. Virol. 63, 2550-2556.
36. Rauscher, F.J. (1962) A virus-induced disease of mice characterized by erythrocytopoiesis and lymphoid leukemia. J. Natl. Cancer Inst. 29, 515-543.
37. Roberts, N.A., Martin, J.A., Kinchington, D., Broadhurst, A.V., Craig, J.C., Duncan, I.B., Galpin, S.A., Handa, B.K., Kay, J., Kröhn, A., Lambert, R.W., Merrett, J.H., Mills, J.S., Parkes, K.E.B., Redshaw, S., Ritchie, A.J., Taylor, D.L., Thomas, G.J. and Machin, P.J. (1990) Rational design of peptide-based HIV proteinase inhibitors. Science 248, 358-361.
38. Rowe, W.P., W.E. Pugh and J.W. Hartley (1970) Plaque assay techniques for murine leukemia viruses. Virol. 42, 1136-1139.
39. Ruprecht, R.M., Chou, T.C., Chipty, F., Sosa, M.G., Mullaney, S., O'Brien, L. and Rosas, D. (1990) Interferon-alpha and 3′-azido-3′-deoxythymidine are highly synergistic in mice and prevent viremia after acute retrovirus exposure. J. Acquir. Immune Defic. Syndr. 3, 591-600.
40. Seelmeier, S., Schmidt, H., Turk, V. and von der Helm, K. (1988) Human immunodeficiency virus has an aspartic-type protease that can be inhibited by pepstatin A. Proc. Natl. Acad. Sci. USA 85, 6612-6616.
41. Ussery, M.A., Black, P.L., Downs, M.B., Lewis, M.G., Lambert, D.M., Dreyer, G.B., Petteway, S.R., Jr. (1991) In vitro and in vivo activity of HIV protease inhibitors in an animal retrovirus model. VII International Conference on AIDS, Florence. Abstract No. WA68.
42. Wlodawer, A., Miller, M., Jaskolski, M., Sathyanarayana, B.K., Baldwin, E., Weber, I.T., Selk, L.M., Clawson, L., Schneider, J. and Kent, S.B. (1989) Conserved folding in retro viral proteases: Crystal structure of a synthetic HIV-1 protease. Science 245, 616-621.
43. Wolff, L. and Ruscetti, S. (1988) The spleen focus-forming virus (SFFV) envelope gene, when introduced into mice in the absence of other SFFV genes, induces acute erythroleukemia. J. Virol. 62, 2158-2163.